Περίληψη:
The bidirectional relationship between cancer and chronic kidney disease (CKD) is complex. Patients with cancer, particularly those with hematological malignancies such as multiple myeloma and lymphoma, are at increased risk of developing acute kidney injury and CKD. On the other hand, emerging evidence from large observational registry analyses have consistently shown that cancer risk is increased by at least 2- to 3-fold in kidney transplant recipients, and the observed increased risk occurs not only in those who have received kidney transplants but also in those on dialysis and with mild- to moderate-stage CKD. The interactions between cancer and CKD have raised major therapeutic and clinical challenges in the management of these patients. Given the magnitude of the problem and uncertainties, and current controversies within the existing evidence, Kidney Disease: Improving Global Outcomes (KDIGO) assembled a global panel of multidisciplinary clinical and scientific expertise for a controversies conference on onco-nephrology to identify key management issues in nephrology relevant to patients with malignancy. This report covers the discussed controversies in kidney disease in hematological malignancies, as well as cancer after kidney transplantation. An overview of future research priorities is also discussed. © 2020 Kidney Disease: Improving Global Outcomes (KDIGO)
Συγγραφείς:
Małyszko, J.
Bamias, A.
Danesh, F.R.
Dębska-Ślizień, A.
Gallieni, M.
Gertz, M.A.
Kielstein, J.T.
Tesarova, P.
Wong, G.
Cheung, M.
Wheeler, D.C.
Winkelmayer, W.C.
Porta, C.
Abu-Alfa, A.K.
Amer, H.
Beutel, G.
Chapman, J.
Chen, X.
Chudek, J.
Cosmai, L.
Danesi, R.
De Stefano, F.
Iseki, K.
Jaimes, E.A.
Jhaveri, K.D.
Jurczyszyn, A.
Kazancioğlu, R.
Kitchlu, A.
Kollmannsberger, C.
Lahoti, A.
Li, Y.
Macía, M.
Matsubara, T.
Mitropoulos, D.
Noiri, E.
Perazella, M.A.
Ronco, P.
Rosner, M.H.
Soler Romeo, M.J.
Sprangers, B.
Stadler, W.M.
Stevens, P.E.
Tesař, V.
Torres da Costa e Silva, V.
Vesole, D.H.
Vijayan, A.
Viklický, O.
Workeneh, B.T.
Yanagita, M.
Zakharova, E.
Conference Participants
Λέξεις-κλειδιά:
allopurinol; bisphosphonic acid derivative; brentuximab vedotin; calcineurin inhibitor; carfilzomib; dasatinib; denosumab; dinaciclib; febuxostat; flavopiridol; lenalidomide; oprozomib; proteasome inhibitor; rasburicase; tacrolimus; venetoclax; xanthine oxidase inhibitor; zoledronic acid, acute lymphoblastic leukemia; amyloidosis; anaplastic large cell lymphoma; cancer screening; Conference Paper; decision making; disease association; disease burden; disease registry; drug efficacy; drug safety; estimated glomerular filtration rate; extracorporeal oxygenation; hematologic malignancy; hemodialysis; human; hypertension; kidney biopsy; kidney disease; kidney function; kidney transplantation; lymphoma; monoclonal immunoglobulinemia; multiple myeloma; myeloma cast nephropathy; nonhuman; outcome assessment; patient education; priority journal; risk assessment; risk factor; thrombocytopenia; thrombotic thrombocytopenic purpura; tumor lysis syndrome; adverse event; chronic kidney failure; hematologic disease; kidney; neoplasm; nephrology; practice guideline, Hematologic Neoplasms; Humans; Kidney; Kidney Transplantation; Neoplasms; Nephrology; Renal Insufficiency, Chronic
